M&A - Resonate Blends, Inc.

Form Type: 10-K/A

Filing Date: 2025-07-07

Corporate Action: Acquisition

Type: Update

Accession Number: 000164117225017976

Filing Summary: Resonate Blends, Inc. has amended its annual report for the fiscal year ended December 31, 2024, highlighting significant developments in its business operations. The company engaged in an acquisition of EMGE on March 14, 2024, which has been pivotal in boosting revenues and modifying the business strategy towards regenerative medicine. The management transition included the appointment of James W. Zimbler as President/CEO, replacing James Morrison, who retains a seat on the Board of Directors. The company reported substantial increases in sales and gross profit compared to the previous year, driven primarily by the business operations of EMGE. However, there exists ongoing uncertainty regarding the company's ability to continue as a going concern due to historical losses and the need for adequate capital to implement future business strategies. The report contains no unresolved staff comments and emphasizes the importance of cybersecurity measures within the company. Financial metrics indicate both a significant increase in income and ongoing operating expenses due to the recent acquisition. Future plans include ongoing research and development in natural health products intended to promote safe and legal human performance enhancements.